COMP <GO>
VSTM vs AVLN // RETURN ON INVESTED CAPITAL (ROIC)
Verastem Inc. (NASDAQ) VS. Avalyn Pharma Inc. (NASDAQ) • 15-METRIC TALLY: VSTM 2
— AVLN 0
■ METRIC PARITY
LAST: $9.59 (-1.64%) • MKT CAP: $1.18B
roic
-35.00%
LAST: $25.60 (-0.12%) • MKT CAP: $1.14B
roic
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VSTM VS. AVLN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VSTM | AVLN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -11.72% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.2 | 44.3 | +16.90 | VSTM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.18B | $1.14B | $47.6M | VSTM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VSTM REV | AVLN REV | VSTM GROSS % | AVLN GROSS % | VSTM FCF | AVLN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $30.9M | $62.5M | — | — | -$137.5M | — |
| FY 2024 | $10.0M | — | — | — | -$104.8M | — |
| FY 2023 | $257.8M | — | — | — | -$86.5M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VSTM // BETA —
AVLN // BETA —